Business Context and Reporting Period
This Form 8-K is a current report filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on July 13, 2018, regarding events occurring on July 10, 2018. The registrant is a Delaware corporation and has elected to be treated as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements.
Material Changes
The primary material change reported is the departure of a director:
- Resignation: Jonah Shacknai resigned as a member of the Board of Directors effective immediately on July 10, 2018.
- Reason: The resignation was due to other business and family commitments.
- Disagreement: The filing explicitly states the resignation was not due to any disagreement with the Board or the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Mr. Shacknai's resignation.
- Confirm whether the resignation triggers any specific corporate governance requirements or bylaws.
- Note that the company is classified as an emerging growth company, which may affect financial reporting standards.